PL1750703T3 - Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuru - Google Patents
Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuruInfo
- Publication number
- PL1750703T3 PL1750703T3 PL05738545T PL05738545T PL1750703T3 PL 1750703 T3 PL1750703 T3 PL 1750703T3 PL 05738545 T PL05738545 T PL 05738545T PL 05738545 T PL05738545 T PL 05738545T PL 1750703 T3 PL1750703 T3 PL 1750703T3
- Authority
- PL
- Poland
- Prior art keywords
- tegafur
- gastrointestinal toxicity
- administration
- toxicity due
- reducing gastrointestinal
- Prior art date
Links
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title abstract 3
- 229960001674 tegafur Drugs 0.000 title abstract 3
- 206010059024 Gastrointestinal toxicity Diseases 0.000 title abstract 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 title abstract 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 235000020937 fasting conditions Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229950000193 oteracil Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56618004P | 2004-04-29 | 2004-04-29 | |
| EP05738545A EP1750703B1 (en) | 2004-04-29 | 2005-04-27 | Method for reducing gastrointestinal toxicity due to the administration of tegafur |
| PCT/JP2005/008450 WO2005105086A1 (en) | 2004-04-29 | 2005-04-27 | Method for reducing gastrointestinal toxicity due to the administration of tegafur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1750703T3 true PL1750703T3 (pl) | 2012-05-31 |
Family
ID=35241420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05738545T PL1750703T3 (pl) | 2004-04-29 | 2005-04-27 | Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuru |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080166427A1 (pl) |
| EP (1) | EP1750703B1 (pl) |
| JP (1) | JP5376758B2 (pl) |
| AT (1) | ATE540679T1 (pl) |
| AU (1) | AU2005237364B2 (pl) |
| CY (2) | CY1112451T1 (pl) |
| DK (1) | DK1750703T3 (pl) |
| ES (1) | ES2378072T3 (pl) |
| HR (1) | HRP20120293T1 (pl) |
| ME (1) | ME01335B (pl) |
| PL (1) | PL1750703T3 (pl) |
| PT (1) | PT1750703E (pl) |
| RS (1) | RS52217B (pl) |
| RU (1) | RU2348409C2 (pl) |
| SI (1) | SI1750703T1 (pl) |
| WO (1) | WO2005105086A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201039816A (en) * | 2009-05-13 | 2010-11-16 | Taiho Pharmaceutical Co Ltd | Treatment of diffuse-type gastric cancers using S-1 and cisplatin |
| EP3792634A3 (en) * | 2009-07-17 | 2021-06-02 | Myriad Genetics, Inc. | Method of assaying 5-fu |
| WO2011022174A1 (en) * | 2009-08-21 | 2011-02-24 | Myriad Genetics, Inc. | Method of processing blood samples containing 5-fu |
| EP2422784A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| EP2422815A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours |
| EP2422848A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| EP3113776B1 (en) * | 2014-03-06 | 2021-01-13 | University of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| JP2017509671A (ja) * | 2014-03-28 | 2017-04-06 | ウニベルシタ デリィ ストゥディ ディ ジェノバ | カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤 |
| CN107613983B (zh) * | 2015-04-30 | 2021-05-04 | 大鹏药品工业株式会社 | 抗肿瘤剂的副作用减轻剂 |
| JP6439761B2 (ja) * | 2016-08-09 | 2018-12-19 | トヨタ自動車株式会社 | ＮＯｘ吸蔵還元触媒の製造方法 |
| CN106619689B (zh) * | 2016-12-30 | 2018-05-01 | 陈晓华 | 一种用于治疗癌症的药物组合物、试剂盒及其应用 |
| EP4153137A4 (en) * | 2020-05-19 | 2024-07-10 | Cellix Bio Private Limited | PHARMACEUTICAL FORMULATIONS AND THEIR MANUFACTURE FOR THE TREATMENT OF CANCER |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635946A (en) * | 1969-07-22 | 1972-01-18 | Solomon Aronovich Giller | N1-(2'-furanidyl)-derivatives of 5-substituted uracils |
| EP0180188B1 (en) * | 1984-10-30 | 1992-04-15 | Otsuka Pharmaceutical Co., Ltd. | A composition for increasing the anti-cancer activity of an anti-cancer compound |
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| EP0443028B1 (en) * | 1989-01-05 | 1993-09-29 | Otsuka Pharmaceutical Co., Ltd. | Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer |
| KR0148589B1 (ko) * | 1991-05-27 | 1998-11-02 | 고바야시 유끼오 | 항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트 |
| US6538001B1 (en) * | 1998-10-12 | 2003-03-25 | Nikolai Borisovich Leonidov | Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect |
-
2005
- 2005-04-27 RS RS20120127A patent/RS52217B/sr unknown
- 2005-04-27 US US11/587,643 patent/US20080166427A1/en not_active Abandoned
- 2005-04-27 AT AT05738545T patent/ATE540679T1/de active
- 2005-04-27 EP EP05738545A patent/EP1750703B1/en not_active Expired - Lifetime
- 2005-04-27 AU AU2005237364A patent/AU2005237364B2/en not_active Ceased
- 2005-04-27 RU RU2006142101/14A patent/RU2348409C2/ru active
- 2005-04-27 JP JP2006539166A patent/JP5376758B2/ja not_active Expired - Fee Related
- 2005-04-27 SI SI200531451T patent/SI1750703T1/sl unknown
- 2005-04-27 HR HR20120293T patent/HRP20120293T1/hr unknown
- 2005-04-27 PT PT05738545T patent/PT1750703E/pt unknown
- 2005-04-27 ME MEP-2012-42A patent/ME01335B/me unknown
- 2005-04-27 PL PL05738545T patent/PL1750703T3/pl unknown
- 2005-04-27 WO PCT/JP2005/008450 patent/WO2005105086A1/en not_active Ceased
- 2005-04-27 DK DK05738545.2T patent/DK1750703T3/da active
- 2005-04-27 ES ES05738545T patent/ES2378072T3/es not_active Expired - Lifetime
-
2012
- 2012-03-07 CY CY20121100222T patent/CY1112451T1/el unknown
- 2012-05-31 CY CY2012014C patent/CY2012014I2/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1750703A1 (en) | 2007-02-14 |
| HRP20120293T1 (hr) | 2012-04-30 |
| CY2012014I1 (el) | 2016-04-13 |
| ATE540679T1 (de) | 2012-01-15 |
| EP1750703B1 (en) | 2012-01-11 |
| RU2006142101A (ru) | 2008-06-20 |
| AU2005237364A1 (en) | 2005-11-10 |
| CY2012014I2 (el) | 2016-04-13 |
| CY1112451T1 (el) | 2015-12-09 |
| WO2005105086A1 (en) | 2005-11-10 |
| AU2005237364B2 (en) | 2010-07-08 |
| EP1750703A4 (en) | 2008-02-27 |
| ES2378072T3 (es) | 2012-04-04 |
| JP2007534634A (ja) | 2007-11-29 |
| SI1750703T1 (sl) | 2012-02-29 |
| RU2348409C2 (ru) | 2009-03-10 |
| JP5376758B2 (ja) | 2013-12-25 |
| US20080166427A1 (en) | 2008-07-10 |
| RS52217B (sr) | 2012-10-31 |
| ME01335B (me) | 2013-12-20 |
| PT1750703E (pt) | 2012-02-23 |
| DK1750703T3 (da) | 2012-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200833370A (en) | Pharmaceutical composition containing low substituted hydroxypropylcellulose | |
| PL369108A1 (pl) | Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenu | |
| WO2007138472A3 (en) | Triazolopyridazine derivatives | |
| WO2006011050A3 (en) | Pyridine derivatives | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| UA96449C2 (en) | Stable laquinimod preparations | |
| TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
| IL193252A0 (en) | N-hydroxyacrylamide compounds | |
| CY1112451T1 (el) | Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης | |
| ZA200603538B (en) | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same | |
| WO2006116148A3 (en) | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse | |
| MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
| MX2007004740A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica. | |
| TNSN08369A1 (en) | Benzimidazole derivatives | |
| MXPA05006889A (es) | Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos. | |
| MX2009007038A (es) | Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales. | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| WO2006072000A3 (en) | Xanthurenic acid derivative pharmaceutical compositoins and methods related thereto | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| MXPA05007253A (es) | Sales novedosas de derivados anticonvulsivantes. | |
| WO2007001839A3 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
| WO2005097757A3 (en) | Nucleoside derivatives and therapeutic use thereof | |
| WO2006004903A3 (en) | 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | |
| TW200633701A (en) | Thioether derivatives, their manufacture and use as pharmaceutical agents | |
| WO2007052167A3 (en) | Stable composition for a pharmaceutical formulation containing olanzapine |